This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00463762
First received: April 17, 2007
Last updated: April 21, 2011
Last verified: April 2011
  Purpose
The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Condition Intervention Phase
Abscess, Intra-Abdominal Cholecystitis Wound Infections Peritonitis Appendicitis Drug: CP-75385-02 Cefoperazone/sulbactam Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.

Resource links provided by NLM:


Further study details as provided by Pfizer:

Enrollment: 0
Study Start Date: May 2007
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patient of age 18 years or older.
  • Patient with intraabdominal/hepatobiliary infection.?

Exclusion Criteria:

  • Patients with known hypersensitivity to penicillins, cephalosporins, cefoperazone or to sulbactam.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00463762

Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00463762     History of Changes
Other Study ID Numbers: A1891004
Study First Received: April 17, 2007
Last Updated: April 21, 2011

Additional relevant MeSH terms:
Infection
Communicable Diseases
Appendicitis
Wound Infection
Peritonitis
Cholecystitis
Acalculous Cholecystitis
Abdominal Abscess
Intraabdominal Infections
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Cecal Diseases
Intestinal Diseases
Wounds and Injuries
Peritoneal Diseases
Gallbladder Diseases
Biliary Tract Diseases
Abscess
Suppuration
Sulbactam
Cefoperazone
Sulperazone
Anti-Bacterial Agents
Anti-Infective Agents
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Urinary
Renal Agents

ClinicalTrials.gov processed this record on September 21, 2017